MX2019013723A - Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer. - Google Patents

Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer.

Info

Publication number
MX2019013723A
MX2019013723A MX2019013723A MX2019013723A MX2019013723A MX 2019013723 A MX2019013723 A MX 2019013723A MX 2019013723 A MX2019013723 A MX 2019013723A MX 2019013723 A MX2019013723 A MX 2019013723A MX 2019013723 A MX2019013723 A MX 2019013723A
Authority
MX
Mexico
Prior art keywords
cancer
combination therapy
treatment
antibodies against
therapy involving
Prior art date
Application number
MX2019013723A
Other languages
English (en)
Inventor
Rita Mitnacht-Kraus
Stefan Denis Jacobs
Magdalena Jadwiga Utsch
Cornelia Adriana Maria Heinz
Christiane Regina Stadler
Özlem Türeci
Ugur Sahin
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48483023&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2019013723(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of MX2019013723A publication Critical patent/MX2019013723A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención proporciona una terapia de combinación para tratar y/o prevenir efectivamente enfermedades asociadas con células que expresan CLDN18.2, que incluyen enfermedades de cáncer tales como cáncer gástrico, cáncer esofágico, cáncer pancreático,cáncer pulmonar, cáncer de ovarios, cáncer de colon, cáncer hepático, cáncer de cabezacuello, y cáncer de la vesícula biliar y metástasis de los mismos.
MX2019013723A 2012-05-23 2014-11-21 Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer. MX2019013723A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2012/002210 WO2013174403A1 (en) 2012-05-23 2012-05-23 Combination therapy involving antibodies against claudin 18.2 for treatment of cancer

Publications (1)

Publication Number Publication Date
MX2019013723A true MX2019013723A (es) 2020-07-20

Family

ID=48483023

Family Applications (5)

Application Number Title Priority Date Filing Date
MX2014014216A MX2014014216A (es) 2012-05-23 2013-05-21 Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer.
MX2020011771A MX2020011771A (es) 2012-05-23 2014-11-21 Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer.
MX2020011782A MX2020011782A (es) 2012-05-23 2014-11-21 Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer.
MX2019013723A MX2019013723A (es) 2012-05-23 2014-11-21 Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer.
MX2020011780A MX2020011780A (es) 2012-05-23 2014-11-21 Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer.

Family Applications Before (3)

Application Number Title Priority Date Filing Date
MX2014014216A MX2014014216A (es) 2012-05-23 2013-05-21 Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer.
MX2020011771A MX2020011771A (es) 2012-05-23 2014-11-21 Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer.
MX2020011782A MX2020011782A (es) 2012-05-23 2014-11-21 Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020011780A MX2020011780A (es) 2012-05-23 2014-11-21 Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer.

Country Status (26)

Country Link
US (2) US20150132253A1 (es)
JP (2) JP6203831B2 (es)
KR (3) KR20240010757A (es)
CN (2) CN109172820B (es)
AR (2) AR091130A1 (es)
AU (2) AU2013265638B2 (es)
BR (1) BR112014028948B8 (es)
CA (1) CA2874032A1 (es)
DK (2) DK2852408T3 (es)
ES (2) ES2637416T3 (es)
FI (1) FI3791896T3 (es)
HK (1) HK1208152A1 (es)
HR (2) HRP20240169T1 (es)
HU (2) HUE036000T2 (es)
IL (2) IL235607A0 (es)
LT (3) LT3791896T (es)
MX (5) MX2014014216A (es)
NZ (2) NZ701585A (es)
PL (1) PL3791896T3 (es)
PT (3) PT3254695T (es)
RS (2) RS61127B1 (es)
RU (1) RU2665321C2 (es)
SG (2) SG11201406977TA (es)
SI (2) SI3791896T1 (es)
UA (1) UA118013C2 (es)
WO (2) WO2013174403A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
DE102004024617A1 (de) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
WO2013167153A1 (en) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
WO2013174404A1 (en) 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
RU2678127C2 (ru) 2012-11-13 2019-01-23 Бионтех Аг Агенты для лечения экспрессирующих клаудин раковых заболеваний
WO2014127785A1 (en) 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2014146672A1 (en) 2013-03-18 2014-09-25 Ganymed Pharmaceuticals Ag Therapy involving antibodies against claudin 18.2 for treatment of cancer
SG11201606843SA (en) * 2014-03-21 2016-10-28 Agency Science Tech & Res Fusion genes in cancer
WO2016180468A1 (en) * 2015-05-11 2016-11-17 Biontech Cell & Gene Therapies Gmbh Claudin-18.2-specific immunoreceptors and t cell epitopes
JP7237344B2 (ja) 2016-06-15 2023-03-13 アイカーン スクール オブ メディシン アット マウント サイナイ インフルエンザウイルス血球凝集素タンパク質及びその使用
WO2018040537A1 (zh) * 2016-08-31 2018-03-08 南京凯地生物科技有限公司 人pd-1基因敲除的cldn18.2 特异性嵌合抗原受体t细胞的制备方法以及应用
CA3058652A1 (en) 2017-04-07 2018-10-11 Icahn School Of Medicine At Mount Sinai Anti-influenza b virus neuraminidase antibodies and uses thereof
EP3732190A1 (en) * 2017-12-27 2020-11-04 Imunami Laboratories Pte. Ltd. Recombinant polypeptides and methods of use thereof
US10150801B1 (en) 2017-12-27 2018-12-11 Imunami Laboratories Pte. Ltd. Recombinant polypeptides and methods of use thereof
SG11202007055QA (en) * 2018-03-08 2020-09-29 Phanes Therapeutics Inc Anti-claudin 18.2 antibodies and uses thereof
US11059887B2 (en) * 2018-05-18 2021-07-13 Lanova Medicines Limited Company Anti-claudin 18.2 antibodies and uses thereof
WO2020038404A1 (zh) * 2018-08-22 2020-02-27 瑞阳(苏州)生物科技有限公司 抗人claudin 18.2单克隆抗体及其应用
CN110857322A (zh) * 2018-08-22 2020-03-03 瑞阳(苏州)生物科技有限公司 抗人claudin 18.2单克隆抗体及其应用
JP2022511394A (ja) * 2018-09-30 2022-01-31 カファ セラピューティクス リミテッド Ｃｌｄｎ１８の抗体及び化学療法薬の併用療法
SG11202104692VA (en) * 2018-11-08 2021-06-29 In8Bio Inc Compositions and methods for treating cancer
CN113166246A (zh) * 2018-12-28 2021-07-23 四川科伦博泰生物医药股份有限公司 一种抗体及其用途
CA3125193A1 (en) * 2018-12-28 2020-07-02 Nanjing GenScript Biotech Co., Ltd. Claudin18.2 binding moieties and uses thereof
JP2022528061A (ja) * 2019-04-01 2022-06-08 ジエンス ヘンルイ メデイシンカンパニー リミテッド 抗クローディン１８．２抗体及びその用途
WO2020219719A1 (en) * 2019-04-24 2020-10-29 Icahn School Of Medicine At Mount Sinai Anti-influenza b virus neuraminidase antibodies and uses thereof
CA3141504A1 (en) * 2019-05-24 2020-12-03 Sanyou Biopharmaceuticals Co., Ltd. Novel cldn18.2 binding molecule
KR20220032077A (ko) * 2019-07-12 2022-03-15 퓨쳐진 바이오파머쓰티컬 (베이징) 코., 엘티디. Cldn18.2 항체 및 이의 용도
US10675332B1 (en) 2019-08-26 2020-06-09 Imunami Laboratories Pte. Ltd. Recombinant polypeptides and methods of use thereof
CA3174588A1 (en) 2020-03-30 2021-10-07 BioNTech SE Rna compositions targeting claudin-18.2
WO2023025147A1 (zh) * 2021-08-23 2023-03-02 南通壹宸生物医药科技有限公司 抗原表位修饰
CN114907482B (zh) * 2021-09-03 2023-02-14 深圳市先康达生命科学有限公司 靶向人Claudin18.2蛋白的单克隆抗体及其应用
WO2023161457A1 (en) 2022-02-27 2023-08-31 Evobright Gmbh Bispecific antibodies against cd277 and a tumor-antigen
WO2024074634A1 (en) 2022-10-06 2024-04-11 BioNTech SE Rna compositions targeting claudin-18.2
WO2024074211A1 (en) 2022-10-06 2024-04-11 BioNTech SE Rna compositions targeting claudin-18.2

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
ES2295228T3 (es) 2000-11-30 2008-04-16 Medarex, Inc. Roedores transcromosomicos transgenicos para la preparacion de anticuerpos humanos.
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
PT3284753T (pt) 2002-10-17 2020-05-04 Genmab As Anticorpos monoclonais humanos contra cd20 para utilização no tratamento da esclerose múltipla
JP2007532684A (ja) * 2004-04-16 2007-11-15 エミスフェアー・テクノロジーズ・インク 活性剤の送達のための８−（２−ヒドロキシフェノキシ）オクチルジエタノールアミン及びその塩
CN101258238B (zh) * 2005-09-08 2014-07-09 迈世耐特股份公司 抗原呈递细胞的活化处理方法
EP1790664A1 (en) * 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
EP1997832A1 (en) * 2007-05-29 2008-12-03 Ganymed Pharmaceuticals AG Monoclonal antibodies against Claudin-18 for treatment of cancer
WO2008152822A1 (ja) * 2007-06-15 2008-12-18 Medinet Co., Ltd. 医薬
AU2009209251B8 (en) * 2008-01-28 2015-03-26 Medimmune Limited Stabilized Angiopoietin-2 antibodies and uses thereof
AU2009273540A1 (en) * 2008-07-25 2010-01-28 Merck Patent Gmbh Method of determination of receptor binding saturation effected by monoclonal antibodies
WO2010141093A2 (en) * 2009-06-04 2010-12-09 The University Of Maryland, Baltimore Co-signaling methods for treating cancers
WO2011090005A1 (ja) * 2010-01-19 2011-07-28 協和発酵キリン株式会社 大腸癌の治療用医薬および治療方法

Also Published As

Publication number Publication date
MX2020011771A (es) 2020-11-24
CA2874032A1 (en) 2013-11-28
JP2015522543A (ja) 2015-08-06
KR20240010757A (ko) 2024-01-24
RS65179B1 (sr) 2024-03-29
SI3791896T1 (sl) 2024-04-30
LT3254695T (lt) 2020-12-28
MX2020011780A (es) 2020-11-24
AU2018201391B2 (en) 2019-12-05
DK3791896T3 (da) 2024-02-12
RU2665321C2 (ru) 2018-09-04
SI3254695T1 (sl) 2021-01-29
WO2013174510A1 (en) 2013-11-28
HK1208152A1 (en) 2016-02-26
UA118013C2 (uk) 2018-11-12
LT3791896T (lt) 2024-03-12
RU2014152115A (ru) 2016-07-20
IL279330A (en) 2021-01-31
NZ701585A (en) 2016-10-28
AR091130A1 (es) 2015-01-14
KR102625189B1 (ko) 2024-01-16
BR112014028948B8 (pt) 2019-09-03
ES2835073T3 (es) 2021-06-21
CN109172820A (zh) 2019-01-11
JP6490764B2 (ja) 2019-03-27
US20150132253A1 (en) 2015-05-14
PT3791896T (pt) 2024-02-12
PT2852408T (pt) 2017-08-25
CN104379166A (zh) 2015-02-25
SG10201609772PA (en) 2017-01-27
BR112014028948B1 (pt) 2019-04-16
IL235607A0 (en) 2015-01-29
PL3791896T3 (pl) 2024-05-13
MX2014014216A (es) 2015-06-23
KR102233344B1 (ko) 2021-03-30
AU2013265638A1 (en) 2014-11-20
AU2013265638B2 (en) 2018-03-01
ES2637416T3 (es) 2017-10-13
HRP20240169T1 (hr) 2024-04-26
JP2018035155A (ja) 2018-03-08
PT3254695T (pt) 2020-12-11
SG11201406977TA (en) 2014-12-30
BR112014028948A2 (pt) 2016-10-25
LT2852408T (lt) 2017-09-25
HUE036000T2 (hu) 2018-06-28
DK2852408T3 (en) 2017-09-11
US20180258180A1 (en) 2018-09-13
JP6203831B2 (ja) 2017-09-27
FI3791896T3 (fi) 2024-02-01
KR20150028777A (ko) 2015-03-16
AR125906A2 (es) 2023-08-23
HRP20201859T1 (hr) 2021-04-02
CN109172820B (zh) 2023-06-20
KR20210025730A (ko) 2021-03-09
RS61127B1 (sr) 2020-12-31
NZ725347A (en) 2018-07-27
CN104379166B (zh) 2018-10-12
HUE054214T2 (hu) 2021-08-30
AU2018201391A1 (en) 2018-03-22
MX2020011782A (es) 2020-11-24
BR112014028948A8 (pt) 2018-12-26
WO2013174403A1 (en) 2013-11-28

Similar Documents

Publication Publication Date Title
MX2019009441A (es) Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer.
MX2019013723A (es) Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer.
MX2017013075A (es) Conjugados de farmaco que comprenden anticuerpos contra claudina 18.2.
MX2020011783A (es) Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer.
EP4242236A3 (en) Monoclonal antibodies against claudin-18 for treatment of cancer
CY1123593T1 (el) Συνδυαστικη θεραπεια που περιλαμβανει αντισωματα κλωντινης 18.2 για τη θεραπεια του καρκινου
JOP20220013A1 (ar) علاج توليفي ينطوي على استخدام الأجسام المضادة ضد claudin 18.2 ومثبطات نقاط الفحص المناعي لعلاج السرطان
CR20230450A (es) Terapia de combinación que implica anticuerpos contra claudina 18.2 para el tratamiento del cáncer